Skip to main content
  • Real-World Watchman LAAO Patients at Higher Risk of Death vs. Pivotal Trials’ Populations – Registry Study

    ‘Excess mortality’ may be related to increased burden of noncardiovascular death

    Atrial fibrillation (AF) patients in real-world clinical practice who underwent left atrial appendage occlusion (LAAO) with the Watchman device were at higher risk of dying than patients in the two pivotal trials used for its U.S. Food and Drug Administration (FDA) approval.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details